This page contains brief information about filgrastim and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Filgrastim is approved to reduce the chance of infection in patients with:
- Neutropenia caused by some types of chemotherapy, including:
- Chemotherapy for acute myeloid leukemia.
- Myeloablative chemotherapy before a bone marrow transplant in patients with non-myeloid cancer.
- Myelosuppressive chemotherapy in patients with non-myeloid cancer.
Filgrastim is also approved to help move stem cells from the bone marrow to the bloodstream so that they can be collected, stored, and then given back to the patient in autologous stem cell transplantation.
Filgrastim is also approved to treat neutropenia that is not caused by cancer treatment.
Filgrastim is also available in a different form called pegfilgrastim. For more information, see the Drug Information Summary for Pegfilgrastim.
More About Filgrastim
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Filgrastim - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Filgrastim - Check for trials from NCI's list of cancer clinical trials now accepting patients.